Female football players often wonder if their performance changes during different parts of their cycle. A new review looked at this question carefully. It examined seven studies involving female athletes. The main goal was to see if vertical jump height changed. This measure tracks how high an athlete can jump. The results showed no statistically significant differences were found between cycle phases. This means jump height stayed the same regardless of timing. The review noted some important limitations. There was substantial heterogeneity regarding how cycle phases were determined. Sample characteristics varied greatly across the studies. Testing protocols were not uniform. Methodological limitations in determining cycle phases also existed. Low statistical power was another concern. These factors mean findings should be interpreted cautiously. Current evidence is insufficient to determine whether cycle phases influence performance. Do not overstate the results. The data does not support higher jump values during specific phases. Athletes can train with confidence that their cycle does not alter this specific outcome.
Current evidence is insufficient to determine whether menstrual cycle phases influence vertical jump performance in female football playersMenstrual cycle phases do not change vertical jump height in female football players
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note insufficient evidence to link menstrual cycle phases with vertical jump performance in female football players.
This systematic review examined seven studies investigating the relationship between menstrual cycle phases and vertical jump performance in female football players. The primary outcome measured included countermovement jump and squat jump height. The analysis compared performance across different phases of the menstrual cycle.
The review found no statistically significant differences in vertical jump height between menstrual cycle phases. The authors did not report specific effect sizes or confidence intervals for these comparisons. Consequently, the data does not support claims of higher performance during specific phases like the follicular or ovulatory periods.
Several limitations were noted by the authors. These include substantial heterogeneity regarding menstrual cycle phase determination procedures, sample characteristics, and testing protocols. Methodological limitations in determining cycle phases and low statistical power further constrain the conclusions. Safety data and adverse events were not reported.
Practice relevance is currently limited. The evidence is insufficient to determine whether menstrual cycle phases influence vertical jump performance in this population. Findings should be interpreted cautiously given the existing gaps in study design and execution.
What this means for you:
Current evidence shows no link between menstrual cycle phases and vertical jump height in female football players. View Original Abstract ↓
This systematic review aimed to evaluate the available evidence on the influence of menstrual cycle (MC) phases on vertical jump performance (countermovement jump and squat jump height) in female football players.
The review was conducted in accordance with PRISMA guidelines and registered in PROSPERO (ID1035357).
A systematic search was performed in PubMed, Scopus, and SPORTDiscus (EBSCO). Studies were included if they involved female football players, assessed vertical jump performance, and compared performance across MC phases. Methodological quality was assessed using a modified Downs & Black checklist for non-interventional studies.
Seven studies met the inclusion criteria. Substantial heterogeneity was observed regarding MC phase determination procedures, sample characteristics, and testing protocols. Although some studies reported higher vertical jump height values during the follicular or ovulatory phases, no statistically significant differences were found.
Current evidence is insufficient to determine whether MC phases influence vertical jump performance in female football players. Findings should be interpreted cautiously due to methodological limitations in MC phase determination and low statistical power. Future research should aim to standardize protocols, use objective hormonal verification, and recruit larger samples.
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251035357, PROSPERO: CRD420251035357.
Mazdutide monotherapy reduces HbA1c and promotes weight loss in Chinese adults with type 2 diabetes over 48 weeks
New Drug Lowers Sugar and Shrinks Weight in Diabetes
Related in Drug Pipeline
Natural metabolites and their combinations may modulate mitochondrial function and provide cardioprotective effects
Natural Compounds May Support Heart Health via Mitochondrial Regulation
This systematic review explores the role of natural metabolites, including flavonoids, alkaloids, saponins, and polyphenols, in cardiovascul…
Natural compounds like flavonoids and polyphenols may help protect heart cells by improving how mitochondria manage energy and reduce inflam…
Icariin improves pain and cartilage scores in murine osteoarthritis, meta-analysis finds
Icariin Shows Potential to Reduce Osteoarthritis Pain in Mice
This meta-analysis of 13 preclinical studies (238 murine subjects) found that Epimedium-derived botanical metabolites, including icariin, si…
A review of studies on mice suggests that icariin, a compound from the Epimedium plant, may reduce inflammation and pain markers in osteoart…
Dihydromyricetin improves lipid profiles, liver enzymes, and glucose in preclinical NAFLD models
Dihydromyricetin Shows Potential for Managing Fatty Liver Disease
This meta-analysis of 13 preclinical studies (316 animals) found that dihydromyricetin (DHM) improved hepatic and serum lipid profiles, live…
Early research in animal models suggests that the compound dihydromyricetin may improve liver health and lipid levels in cases of fatty live…
Complement-targeted therapies show clinical activity in C3G and aHUS including 68% reduction in proteinuria
Newer therapies show promise for rare kidney and blood conditions
This narrative synthesis of 38 studies evaluates complement-targeted therapies for patients with C3G and aHUS. The review highlights positiv…
Newer treatments like iptacopan and pegcetacoplan may help manage serious kidney issues and blood disorders in specific patient groups.
From Other Specialties
Disitamab vedotin and tislelizumab combination achieved remission of skin metastasis in a patient with bladder carcinoma
Drug Combo Clears Skin Metastasis in Bladder Cancer
This case report describes a 70-year-old man with muscle-invasive bladder carcinoma treated with a combination of disitamab vedotin and tisl…
A man's bladder cancer skin spread vanished after a two-drug combo, but it's just one case.
Alloplastic implants show lower risk of ectropion and malposition in orbital floor reconstruction
Alloplastic implants may lower eye surgery risks
This meta-analysis of 2119 patients evaluates the safety and efficacy of alloplastic implants versus autologous bone grafts for orbital floo…
A new analysis finds synthetic implants for orbital floor fractures may reduce eyelid drooping and implant movement compared to bone grafts.
ACDF with stand-alone PEEK cages results in shorter operative times than zero-p implants
PEEK Cages May Shorten Surgery Time for Cervical Neck Issues
This meta-analysis of 727 patients with cervical degenerative disease compares stand-alone PEEK cages to zero-p implants in ACDF procedures.…
A review of 727 patients suggests that using PEEK cages during neck surgery may lead to shorter operation times for certain cervical conditi…
Targeted strategies like senolytics and PFKFB3 blockers show preclinical efficacy in chronic kidney disease
New research explores how cells drive chronic kidney disease
This narrative review explores the mechanisms of necroptotic tubular epithelial cell death and glycolytic reprogramming in chronic kidney di…
Scientists identified a self-amplifying cycle of cell death and aging that drives scarring in chronic kidney disease.